X

Feature/News

Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018

This report originally appeared on cdc.gov. To view the full report, click here. Additionally, you can find the original report for download here: Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018 (43 downloads)

On December 3rd, a new Morbidity and Mortality Weekly Report (MMWR)  was released highlighting vital signs for HIV virus testing, suppression, and pre-exposure prophylaxis.

Following is a brief summary of the article, “Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018.”

Summary

What is already known about this topic?

The approximately 38,000 new human immunodeficiency virus (HIV) infections that occur annually in the United States are preventable through testing, treatment, and preexposure prophylaxis (PrEP). A proposed initiative seeks to reduce new infections by at least 90% by 2030. The targets for the initiative are at least 95% for testing and treatment and 50% for PrEP.

What is added by this report?

In 2017, 85.8% of persons with HIV infection had received a diagnosis, and 62.7% of persons with diagnosed HIV infection had a suppressed viral load. In 2018, PrEP had been prescribed to 18.1% of persons with indications.

What are the implications for public health practice?

Accelerated efforts to diagnose, treat, and prevent HIV infection are urgently needed.

Read the full report. 

X